ImmunoGen, Inc. (IMGN) Receives $7.46 Average Price Target from Brokerages

ImmunoGen, Inc. (NASDAQ:IMGN) has been given an average recommendation of “Hold” by the eleven analysts that are currently covering the company, Marketbeat reports. Three analysts have rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $7.46.

Several equities analysts have recently commented on the company. Canaccord Genuity reiterated a “buy” rating and set a $10.00 target price (up from $8.00) on shares of ImmunoGen in a research note on Wednesday, August 30th. Cowen and Company reiterated a “hold” rating on shares of ImmunoGen in a research note on Tuesday, August 29th. Cantor Fitzgerald reiterated a “hold” rating and set a $5.00 target price on shares of ImmunoGen in a research note on Monday, September 25th. ValuEngine cut ImmunoGen from a “hold” rating to a “sell” rating in a research note on Thursday, September 21st. Finally, Leerink Swann reiterated a “buy” rating on shares of ImmunoGen in a research note on Tuesday, August 29th.

In related news, VP Craig Barrows sold 14,600 shares of the company’s stock in a transaction that occurred on Wednesday, September 13th. The stock was sold at an average price of $6.95, for a total transaction of $101,470.00. Following the sale, the vice president now directly owns 51,100 shares of the company’s stock, valued at approximately $355,145. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 6.51% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Arrowstreet Capital Limited Partnership acquired a new stake in shares of ImmunoGen during the 2nd quarter valued at approximately $102,000. Gould Asset Management LLC CA acquired a new stake in shares of ImmunoGen during the 2nd quarter valued at approximately $107,000. Intl Fcstone Inc. acquired a new stake in shares of ImmunoGen during the 2nd quarter valued at approximately $115,000. Aperio Group LLC raised its position in shares of ImmunoGen by 45.1% during the 2nd quarter. Aperio Group LLC now owns 16,797 shares of the biotechnology company’s stock valued at $119,000 after acquiring an additional 5,221 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. acquired a new stake in shares of ImmunoGen during the 2nd quarter valued at approximately $126,000. 73.03% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “ImmunoGen, Inc. (IMGN) Receives $7.46 Average Price Target from Brokerages” was first posted by Week Herald and is owned by of Week Herald. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://weekherald.com/2017/11/15/immunogen-inc-imgn-receives-7-46-average-price-target-from-brokerages.html.

Shares of ImmunoGen (NASDAQ:IMGN) traded up 1.142% on Friday, reaching $5.755. 3,257,580 shares of the company were exchanged. The stock’s market capitalization is $515.63 million. The company has a 50-day moving average price of $6.64 and a 200 day moving average price of $5.81. ImmunoGen has a 1-year low of $1.51 and a 1-year high of $8.84.

ImmunoGen (NASDAQ:IMGN) last released its earnings results on Friday, July 28th. The biotechnology company reported ($0.10) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.07. The business had revenue of $39.02 million for the quarter, compared to analysts’ expectations of $30.59 million. The business’s quarterly revenue was up 426.6% compared to the same quarter last year. During the same quarter last year, the company posted ($0.53) earnings per share. On average, analysts forecast that ImmunoGen will post ($0.72) EPS for the current fiscal year.

About ImmunoGen

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

Analyst Recommendations for ImmunoGen (NASDAQ:IMGN)

Receive News & Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply